JSKN033 clinical trials
Also written JSKN033.
How each study uses JSKN033 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the JSKN033 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test JSKN033.
- Dec 2026JSKN033 in Chinese Subjects with Advanced Malignant TumorsPhase 1/2 · Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Aug 2027A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung CancerPhase 2 · Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Oct 2027JSKN033 Combination Therapy in Subjects With Advanced Cervical CancerPhase 2 · Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Studies
Open first, then newest update. How each study uses JSKN033 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical CancerNot yet recruitingPhase 3Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT07797153Written as JSKN033
- JSKN033 Combination Therapy in Subjects With Advanced Cervical CancerNot yet recruitingPhase 2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT07497074Written as JSKN033
- A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung CancerNot yet recruitingPhase 2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT07283198Written as JSKN033 Injection
- JSKN033 in Chinese Subjects with Advanced Malignant TumorsNot yet recruitingPhase 1/2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT06770881Written as JSKN033
- JSKN033 in Patients With Advanced or Metastatic Solid Malignant TumorsTerminatedPhase 1/2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT06226766Written as JSKN033 Injection